Upregulation of GR and β-catenin in mCRPC proceeds despite the declining influence of AR signaling, particularly in neuroendocrine differentiated PCa, characterized by AR loss and resistance to anti-AR therapy [69,70]. The gene discussed is AR; the disease is posterior cortical atrophy.